Bayer expands Kerendia development program as a treatment for heart failure

Bayer announced it is further investing in MOONRAKER- its clinical development program to investigate Kerendia or finerenone, as a potential treatment for heart failure, HF, with the initiation of three additional investigator-sponsored collaborative studies.1,2,3,4 Recruiting approximately 15,000 patients, MOONRAKER is expected to be one of the largest heart failure study programs to date…In addition to the ongoing Phase III study FINEARTS-HF, investigating finerenone versus placebo on top of standard of care or SoC, in more than 6,000 HF patients with mildly reduced or preserved ejection fraction,1 the new studies will evaluate the efficacy and safety of finerenone in approximately 9,000 additional HF patients with reduced HfrEF , mildly reduced , and/or preserved ejection fraction “With the addition of the REDEFINE-HF, CONFIRMATION-HF and FINALITY-HF studies to the MOONRAKER heart failure clinical trial program, we aim to gain a comprehensive understanding of the potential of finerenone for the treatment of heart failure, examining its efficacy and safety across a broad spectrum of patients and clinical settings,” said Dr. Michael Devoy, Chief Medical Officer, Bayer. “The studies will complement our Phase III FINEARTS-HF study, and we hope the findings will provide additional guidance around the potential clinical implementation of finerenone.”